insights_auto
LGND の下落理由: 2.68%?
さらに詳しくchevron_right
LGND:NASDAQ
リガンド・ファーマシューティカルズ
$303.99
arrow_downward
-2.68%(-8.38) 1 日
10月1日, 12:49:31 GMT-4 · USD
search
すべての記号
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_autoLGND の上位の分析情報を生成しています...
始値
$309.82
高値
$312.05
安値
$301.48
時価総額
60.60億
平均出来高
23.13万
取引量
11.56万
株価収益率
32.33
52 週高値
$326.63
52 週安値
$175.56
EPS
$9.40
ベータ版
1.03
発行済株式数
1993.60万
従業員数
47
始値
$309.82
高値
$312.05
安値
$301.48
時価総額
60.60億
平均出来高
23.13万
取引量
11.56万
株価収益率
32.33
52 週高値
$326.63
52 週安値
$175.56
EPS
$9.40
ベータ版
1.03
発行済株式数
1993.60万
従業員数
47
ニュース記事
情報源: ウェブソース、ニュース パートナー
Yahoo Finance
·
5 時間前
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts
Investing.com UK
·
2 日前
Form 4 Ligand Pharmaceuticals Incorporated For: 28 September By Investing.com
プロフィール
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
リガンド・ファーマシューティカルズ について